You are here

Press Release Archive

- Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit

(BUSINESS WIRE)--Pfizer announced today that it has named Mace L. Rothenberg, M.D. as Senior Vice President, Clinical Development and Medical Affairs for its Oncology Business Unit. Dr. Rothenberg comes to Pfizer from Vanderbilt where he was Professor of Medicine at the Vanderbilt University Medical Center and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center. In his new role, Dr. Rothenberg will be

- Pfizer Reports Third-Quarter 2008 Results

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter Year-to-Date 2008

- Pfizer and UCB Announce Formation of New Company 'Cyclofluidic' to Accelerate Drug Discovery Process

(BUSINESS WIRE)--Pfizer Ltd (NYSE:PFE) (LSE:PFZ) and UCB today announced the formation of Cyclofluidic, a breakthrough technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time. The UK Government’s Technology Strategy Board has helped facilitate this innovative arrangement between Pfizer and UCB and will

- Pfizer Reaches Agreements in Principle to Resolve Litigation Involving Its NSAID Pain Medications

(BUSINESS WIRE)--Pfizer Inc announced today that it has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory (NSAID) pain medication Bextra, which Pfizer voluntarily withdrew from the U.S. market in 2005. Additionally, following key court rulings in favor of Celebrex, claims regarding Celebrex, an

- New Data across Pfizer's Pain and Inflammation Portfolio to Be Presented at Upcoming ACR Meeting

(BUSINESS WIRE)--Pfizer will highlight several presentations and posters across a spectrum of pain and inflammatory conditions at the American College of Rheumatology (ACR) annual meeting in San Francisco from October 25 to 29, 2008. Late-breaking abstracts for Pfizer’s investigational JAK-inhibitor CP-690,550 and Celebrex (celecoxib capsules) will be presented at the meeting. Pfizer will also host an investor briefing during

- Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements over Four Years

(BUSINESS WIRE)--Results of the UPLIFT® (Understanding Potential Long-term Impacts on Function with Tiotropium) trial, showed that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder), sustained improvements in lung function for up to 4 years as measured by FEV1 (p

- Aetna and Pfizer Present ''State of Motion'' Health Fair in Hartford to Encourage Families to Adopt Healthy Lifestyles

(BUSINESS WIRE)--Aetna and Pfizer Inc are co-sponsoring a recreational health fair for Hartford families on October 18 to raise awareness of the importance of healthy lifestyles in the family and the community. The free event will run from 10 a.m. to 3 p.m., rain or shine, in Hartford's Bushnell Park. More than half of adults in Connecticut are overweight or obese. Since 1990, the number of obese adults in Connecticut has

- EPA Honors Pfizer for Reducing Greenhouse Gas Emissions

(BUSINESS WIRE)--The U.S. Environmental Protection Agency (EPA) honored Pfizer Inc today in recognition of the company’s award-winning Energy and Climate Change Program, which reduced total greenhouse gas emissions by 43 percent per million dollars of revenue from 2000 to 2007. These reductions, which exceeded Pfizer’s original goal of 35 percent, were achieved in partnership with the EPA’s Climate Leaders Program

- Pfizer Invites Public to View and Listen to Webcast of October 28 Analyst and Investor Meeting at ACR

(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a presentation by Pfizer’s pain and inflammation leadership team at an analyst and investor meeting on Tuesday, October 28, 2008 at 6:00 p.m. Pacific Daylight Saving Time, in connection with the annual meeting of the American College of Rheumatology (ACR). To view and listen to the webcast, visit our web site homepage

- Pfizer Invites Public to View and Listen to Webcast of October 21 Conference Call with Analysts

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 21, 2008. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2008 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report

- Pfizer Shows Accelerating Pipeline with Significant Growth in Late-Stage Clinical Development

(BUSINESS WIRE)--Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company’s growth, productivity and performance goals. The pipeline now includes 114 programs, from Phase 1 through Registration. The number in late-stage (Phase 3) development has grown from 16 to 25 over the past six months. In total, 31 programs advanced to the next stage of

- Established Safety Profile of Spiriva(R) Confirmed by 30 Rigorously Controlled Clinical Trials

(BUSINESS WIRE)--Boehringer Ingelheim and Pfizer have released a new analysis of 30 rigorously controlled clinical trials confirming the long term safety profile of Spiriva® (tiotropium). The new and expanded safety data contradicts the conclusions about tiotropium in an article by Singh et al. published in the 24 September issue of the Journal of the American Medical Association.1 Both companies considered it important to

- Grameen Health and Pfizer Announce Novel Partnership to Explore Sustainable Healthcare Delivery Models for the Developing World

(BUSINESS WIRE)--Pfizer Inc and Grameen Health, an affiliate of Grameen Bank, the pioneering micro-financing organization in Bangladesh that shared the Nobel Peace Prize in 2006 for its work to alleviate poverty, today announced that they will work together to identify sustainable models for healthcare delivery in the developing world. The partners will jointly evaluate ways to improve Grameen Health’s existing healthcare

- Pfizer Recognized as Leader in Improving Climate Change for Second Consecutive Year

(BUSINESS WIRE)--Pfizer Inc announced today that for the second consecutive year it was recognized for its approach to improving the environment by being named to the Climate Disclosure Leadership Index (CDLI) by the Carbon Disclosure Project (CDP). The CDP is a not-for-profit coalition of 385 global investors with $57 trillion in assets under management. Pfizer was one of 383 Fortune 500 companies -- and one of nine in the chemical

- MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy

(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) and Pfizer Inc (NYSE: PFE) announced today that MannKind will transition certain Exubera patients with a continuing need for inhaled insulin to MannKind’s inhaled insulin product, Technosphere® Insulin. Technosphere Insulin is an investigational product that has recently completed Phase 3 clinical trials. In October 2007, Pfizer announced that it would

- Pfizer Launches New Medicine Safety Website to Help Healthcare Professionals and Patients Make Better Informed Decisions about Treatment Options

(BUSINESS WIRE)--Pfizer Inc announced today the launch of a new interactive online educational resource designed to give healthcare professionals, medical students, patients, patient advocates and the general public more information about medicine safety, and, in turn, more confidence when making decisions about appropriate treatment options. “We want to increase understanding of the industry’s system for ensuring

- Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008

(BUSINESS WIRE)--Pfizer announced today updated safety and efficacy results surrounding its investigational compound, CP-751,871, in patients with non-small cell lung cancer (NSCLC). These results, along with supporting correlative science data, were presented at the 33rd European Society for Medical Oncology (ESMO) congress in Stockholm, Sweden. Results from a Phase II, randomized, non-comparative study, “Addition

- Pfizer Animal Health Adds Former Schering-Plough Products to European Portfolio

(BUSINESS WIRE)--Pfizer Animal Health today announced that its acquisition of multiple product franchises in Europe from the Schering-Plough Corporation has been completed and approved by the European Commission. Pfizer has acquired these assets for approximately euro 116 million in cash. The acquisition adds both biological and pharmaceutical products across the major animal health species including cattle, swine, equine and companion

- Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial

(BUSINESS WIRE)--Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in adults, including the U.S. new drug application (NDA) and the European marketing authorization application (MAA). Following feedback from regulatory authorities, the company plans to conduct an additional Phase 3 clinical trial with dalbavancin for the

- Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to Cancer Care and Research

(BUSINESS WIRE)--Pfizer announced today that important study results involving the company’s leading anticancer agent, SUTENT® (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12—16 September 2008. Researchers will present results of several analyses evaluating the cost


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.